Neuroimaging Core

神经影像核心

• 批准号: 10450021
• 负责人: KEJAL KANTARCI
• 金额: $ 83.56万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10450021
• 关键词: Alzheimer' s Disease; Biological Markers; Brain; Brain imaging; C9ORF72; Clinical; Clinical Trials; Clinical Trials Cooperative Group; Communities; Confidentiality of Patient Information; Consult; Data; Data Analyses; Dementia; Diagnosis; Diffusion; Disease; Ensure; Ethics; Frontotemporal Lobar Degenerations; Functional Magnetic Resonance Imaging; Funding; Future; Genes; Genetic; Goals; Image; Image Analysis; Imaging technology; Individual; Laboratories; Leadership; Light; Longitudinal Studies; MRI Scans; Magnetic Resonance Imaging; Measurement; Measures; Nerve Degeneration; Neurodegenerative Disorders; Participant; Patients; Perfusion; Pharmaceutical Preparations; Preparation; Procedures; Process; Protocols documentation; Quality Control; Recording of previous events; Research; Research Personnel; Research Project Grants; Resources; Role; Scanning; Site; Staging; Standardization; Symptoms; Testing; Work; catalyst; clinical research site; cohort; data management; data sharing; design; diagnostic criteria; experience; image archival system; image processing; imaging biomarker; imaging study; innovation; innovative technologies; multimodality; mutation carrier; neuroimaging; neuropathology; programs; technology development; tool

ABSTRACT – ARTFL LEFFTDS Longitudinal FTLD: NEUROIMAGING CORE Brain imaging has taken on critical roles in dementia research, including its use for diagnosis and staging of multiple neurodegenerative disorders and enrichment of study groups for clinical trials. In the earliest stages of neurodegenerative disease, when symptoms have not yet developed, imaging and other biomarkers may be the only disease indicators that can be used to quantify drug effects in clinical trials, and imaging may ultimately guide use of approved treatments. The goal of this project is to create a neuroimaging core for the ARTFL LEFFTDS Longitudinal FTD (ALLFTD) project. The core will ensure optimal quality and efficient, innovative use of brain images collected for the project by designing and ensuring faithful application of a standardized acquisition protocol across the 19 clinical sites and promoting the application of advanced imaging technology in the FTLD field. We will design acquisition protocols that optimally utilize the scanner capabilities for the advanced sequences at each study site and allow harmonization of images across the study. All scans, along with the quality control information, will be made available to the public through the Laboratory of Neuroimaging (LONI). We will provide innovative technology and resources for understanding the contribution of MAPT, GRN or C9orf72 genes to neurodegeneration in FTLD and reliable estimates of changes in cortical volume in asymptomatic and symptomatic mutation carriers as well as patients with sporadic FTLD, in preparation for future clinical trials. We will provide resources for establishing the topographic distribution of brain structural changes across the FTLD spectrum, and work with LONI to maintain an archive of images and establish appropriate processes to ensure ethical and efficient access to the data. The Neuroimaging Core will pursue the following aims: 1) Establish and maintain a harmonized MRI acquisition protocol for acquisition and quality control of T1, FLAIR, T2, diffusion, ASL-perfusion, and task free functional MRI across 19 participating sites and supply MRI scans for research projects and the research community, while protecting patient confidentiality. 2) Operate a standardized quality control, image processing and data analysis program. 3) Supply processed cross-sectional and longitudinal data including regional cortical volume measurements and longitudinal change in cortical volume on serial MRIs for ALLFTD Projects 1 and 2, and also share these data with the research community. 4) Consult with ALLFTD and outside researchers and share research tools to facilitate use of imaging data for analysis. The leaders of this proposed neuroimaging core have extensive experience with image analysis and leadership of multicenter imaging efforts, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), which set the standard for multisite imaging studies in dementia. This will help to ensure smooth conduct of the imaging activities for ALLFTD.

摘要- ARTFL LEFFTDS纵向FTLD：神经成像核心 脑成像在痴呆症研究中发挥了关键作用，包括用于诊断和分期。 多种神经退行性疾病和丰富临床试验的研究组。在早期阶段， 神经退行性疾病，当症状尚未发展时，成像和其他生物标志物可能是 在临床试验中唯一可用于量化药物作用的疾病指标， 最终指导批准的治疗方法的使用。该项目的目标是为神经系统创建一个神经成像核心。 ARTFL LEFFTDS纵向FTD（ALLFTD）项目。核心将确保最佳的质量和效率， 通过设计和确保忠实地应用为项目收集的大脑图像， 在19个临床研究中心建立标准化采集协议，并推广先进的 FTLD领域的成像技术。我们将设计最佳利用扫描仪的采集协议 每个研究中心的高级序列功能，并允许在整个研究中心协调图像。 study.所有的扫描，连同沿着的质量控制信息，将通过 神经影像学实验室（LONI）我们将提供创新的技术和资源， MAPT、GRN或C9 orf 72基因对FTLD神经退行性变的贡献， 无症状和有症状突变携带者以及 散发性FTLD，为将来的临床试验做准备。我们会提供资源， 大脑结构变化在FTLD谱中的地形分布，并与LONI合作， 建立图像档案，并建立适当的程序，以确保以合乎道德和有效的方式访问数据。 神经影像学核心将追求以下目标：1）建立和维持协调的MRI 用于T1、FLAIR、T2、弥散、ASL灌注和无任务的采集和质量控制的采集协议 在19个参与站点进行功能性MRI，并为研究项目和研究提供MRI扫描。 同时保护患者隐私。2)操作标准化质量控制、图像处理 数据分析程序。3)提供经过处理的横截面和纵向数据，包括区域 ALLFTD项目中连续MRI的皮质体积测量和皮质体积的纵向变化 1和2，并与研究界分享这些数据。4)咨询ALLFTD和外部 研究人员和共享研究工具，以促进使用成像数据进行分析。这方面的领导者 建议的神经影像学核心具有丰富的图像分析经验，并领导多中心 影像学方面的努力，包括阿尔茨海默病神经影像学倡议（ADNI），它为 痴呆症的多部位成像研究。这将有助于确保成像活动的顺利进行， 一切顺利。